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Abstract
Background: We present the first population genetic analysis of homologous loci from two sympatric human malaria
parasite populations sharing the same human hosts, using full-length sequences of ama1 genes from Plasmodium vivax and
P. falciparum collected in the Venezuelan Amazon.
Methodology/Principal Findings: Significant differences between the two species were found in genetic diversity at the
ama1 locus, with 18 distinct haplotypes identified among the 73 Pvama1 sequences obtained, compared to 6 unique
haplotypes from 30 Pfama1 sequences, giving overall diversity estimates of h=0.9091, and h=0.538 respectively. Levels of
recombination were also found to differ between the species, with P. falciparum exhibiting very little recombination across
the 1.77kb sequence. In contrast, analysis of patterns of nucleotide substitutions provided evidence that polymorphisms in
the ama1 gene of both species are maintained by balancing selection, particularly in domain I. The two distinct population
structures observed are unlikely to result from different selective forces acting upon the two species, which share both
human and mosquito hosts in this setting. Rather, the highly structured P. falciparum population appears to be the result of
a population bottleneck, while the much less structured P. vivax population is likely to be derived from an ancient pool of
diversity, as reflected in a larger estimate of effective population size for this species. Greatly reduced mosquito transmission
in 1997, due to low rainfall prior to the second survey, was associated with far fewer P. falciparum infections, but an increase
in P. vivax infections, probably due to hypnozoite activation.
Conclusions/Significance: The relevance of these findings to putative competitive interactions between these two
important human pathogen species is discussed. These results highlight the need for future control interventions to employ
strategies targeting each of the parasite species present in endemic areas.
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Introduction
Plasmodium vivax infection causes 132–391 million cases each year
worldwide, with a significant, but under-reported burden of severe
malaria requiring hospitalisation [1]. Vivax malaria is endemic in
bothtropicalandsometemperateregionsanditisestimatedthat2.6
billion people are at risk from infection each year [2]. P. vivax is
sympatric with P. falciparum in many regions often with P. ovale and/
or P. malariae also [3]. The majority of laboratory and field studies of
human malaria have been concerned with P. falciparum, due to the
development of methods for continuous in vitro culture of this
species, and the large number of genetic markers available [1,4].
However the current elucidation of the P. vivax genome, and the
recent development of improved in vitro drug sensitivity testing
protocols [5] are cause for optimism regarding future research into
this important human pathogen.
Control regimes targeting any particular malaria species must
also consider knock-on effects this may have on other sympatric
Plasmodium species. The effects a circulating patent species may
have on liver-stage or sub-patent blood-stage infection by other
species remains unclear. Working in Vanuatu, Maitland et al. [6]
found that although the individual prevalence of P. vivax and P.
falciparum fluctuated, the overall burden of malaria remained
constant, suggesting that there was direct interaction between the
two species. In regions where more than one species co-circulate, it
has also been observed that fewer than expected mixed infections
occur [6,7,8]. A suggested explanation for these observations is
that an erythrocytic P. falciparum infection actively suppresses
subsequent P. vivax infections that emerge from the liver [7]
through non-specific effectors such as cytokines, and cross-species
immune responses [7,9]. When this suppression is lifted, either
through drug treatment or host-mediated responses, there can be a
swift expansion of P. vivax within the host [10]. Although a
particular species, such as P. falciparum, may be reduced in
prevalence or even eradicated in a particular setting, other malaria
species, such as P. vivax, may survive the intervention through the
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proliferate through the human population to occupy the niche
vacated by the targeted species. Thus although mortality due to P.
falciparum may be reduced by such an intervention, malaria
morbidity may continue; merely the species-specific dynamics
within the region have been altered. In the light of drug resistance
in P. vivax, [11,12] and also possibly P. malariae [13,14], control
measures for the future that include novel drug and vaccine
development should therefore consider all local sympatric
Plasmodium spp. [3,15].
To be effective in areas with multiple Plasmodium species,
vaccine-based interventions would ideally generate protective
responses against clinical episodes from each species present.
Much vaccine development has focused on those antigens
expressed during the merozoite stage, the form that invades
circulating erythrocytes and reticulocytes during clinical stages of
infection. Merozoite antigens are under considerable investigation
as potential vaccine candidates despite extensive sequence
variation within and between populations, as there is some
evidence that antibodies raised to one variant are cross-reactive
with other variants from the same species [16,17]. Whether this
cross-reactivity also indicates cross-isolate protection in subsequent
infection with different variants is not known. A current vaccine
candidate for both P. falciparum and P. vivax is the merozoite-
expressed apical membrane antigen (AMA1). Widespread varia-
tion of the genes encoding AMA1 proteins from different
populations and in more than one species have been reported,
providing evidence that this gene, ama1, is under significant
selection pressures in natural populations [15,18,19]. A number of
studies have investigated polymorphism within Pfama1 to assist
development of anti-AMA1 vaccines able to elicit broad protective
responses [18,20], and this has lead to the development of multiple
Pfama1 antigens for simultaneous vaccination in order to overcome
this diversity [17]. Analyses of diversity have also been carried out
Pvama1, but these have used parasite isolates collected at hospital
clinics, rather than cross-sectional P. vivax population samples
[3,15,21]. There are no studies that examine ama1 diversity
simultaneously in both species in a setting where P. vivax and P.
falciparum are sympatric.
We have been engaged in analysis of genetic diversity in malaria
parasite populations circulating among forest-dwelling communi-
ties along the Padamo River basin in southern Venezuela. These
studies have shown that the P. falciparum population in this area
exhibits inter-genic linkage disequilibrium, and is dominated by a
small number of multi-locus genotypes, whereas the P. vivax
population appears more diverse [22,23,24]. Here we present full-
length sequence analysis of Pvama1 and Pfama1 from cross-
sectional surveys of malaria parasites co-circulating among the
human population between 1995 and 1997. We use these
homologous sequence datasets to directly compare genetic
structure between the two parasite populations, to contrast
selective forces acting upon the two genes, and to examine any
evidence of direct interplay between the two species in this setting
of mesoendemic, sympatric transmission among two geographi-
cally defined parasite populations sharing the same human hosts.
Materials and Methods
Ethical approval for the original survey was obtained from the
Ethics committee of the Venezuelan Ministry of Health, and the
Ethics Committee of the London School of Hygiene & Tropical
Medicine in 1995. The study protocol was also approved by
CAICET (Centro Amazo ´nico de Investigacio ´n y Control de
Enfermedades Tropicales); the Direccio ´n de Malariologa y
Saneamiento Ambiental and the Regional Health Service, each
institution providing a written statement of approval and support.
Oral and written informed consent was obtained from the
community leaders once the study was explained to the assembled
community population, one community at a time.
Sample collection
Between October 1995 and November 1997, blood samples and
census data from all individuals in nine villages along the Padamo
River, Amazon Basin, Venezuela, were collected in each of two
cross-sectional surveys [23]. Due to the low P. falciparum prevalence
found in 1997, the boundaries of the survey were extended in the
second survey to include an additional large village. More than
90% of the surveyed population gave informed consent to
participate: 708 individuals in 1996 and 945 in 1997. Blood
samples from all participants were obtained for microscopy and
collected onto filter paper for malarial genetic analyses. Individuals
shown to have malaria parasites were treated accordingly, as
described [23].
DNA extraction
DNA was extracted from all available filter paper blood-spots
corresponding to slide-positive samples as previously described
[25]. Sufficient P. falciparum DNA samples for amplification and
sequencing were not available from the 1997 survey. Samples that
did not easily or consistently amplify were re-extracted using a
commercially available kit (Qiagen) and this DNA source was used
instead.
Pvama1 and Pfama1 amplification and sequencing
Pvama1-specific primers were designed based on the published P.
vivax sequence (GENBANK accession L27504) to amplify 1663 bp
in a nested PCR approach. Previously published Pfama1-specific
primers [19] were used in a nested PCR to amplify 1770 bp of the
Pfama1gene.PCRpositive samples were re-amplifiedina 50 ml nest
2 reaction which was prepared for direct sequencing by ethanol
precipitation into 20 ml. New sequencing primers for Pvama1 were
designed based on L27504. Previously published sequencing
primers for Pfama1 [19] were used in conjunction with amplification
primers to determine full-length sequences (Perkin-Elmer BigDye
3.1). Sequencing reactions were cleaned by precipitation in 0.3 M
NaAc, 125 mM EDTA and 2.2 volumes of ethanol, and analysed
on an ABI prism 3730 automated capillary sequencer. Amplifica-
tion and sequencing primers used in this study are presented in
Table 1, with the PCR conditions used.
Editing and assembling of sequence products
Each sequence from the same isolate was assembled and initially
edited into a full-length contig with at least double coverage using
SeqMan
TMII, and EditSeq
TM (DNAStar Inc, Madison, WI).
Secondary editing was done to confirm polymorphisms only
occurring once (singletons) within the population using MegA-
lign
TM (DNAStar Inc). Sequencing was repeated to confirm
singletons and for isolates that did not have full-length double
reads. A single ama1 contig could not be determined for two
isolates (one P. falciparum and one P. vivax). DNA was re-extracted
and each was fully processed independently. In both cases, the two
DNA extractions each yielded two different sequences that were
already represented in the population, making them unlikely to be
PCR artefacts, but rather indicating the infections were comprised
of more than one genotype of that respective species. Confirmed
single genotype data was exported as a PAUP alignment for
statistical analyses, computed using DnaSP v.4.10 software.
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In the 1997 survey, an extra village to the south of the main
survey region, Koshirowetheri, was included for data collection
and contributed a further 250 participants. To analyse data
between the two years on a like-for-like basis, sequences from
Koshirowetheri were at first excluded. Sequences of Pvama1 from
the original survey region from 1997 and those from Koshir-
owetheri in 1997 were subsequently compared by tests of
departure from neutrality and analysis of within-population
diversity to identify any significant differences between them that
would preclude all Pvama1 sequences obtained in the 1997 survey
being treated as a single dataset.
The binomial probability was used to test whether the number
of different haplotypes, and the relative frequency of the most
common haplotype in each case, was significantly different
between the Pfama1 and Pvama1 datasets. As 6 distinct Pfama1
haplotypes (successes) were described in 30 sequences (trials) the
probability of success in this dataset is 0.20. The probability that
the observed number of successes in the Pvama1 dataset was within
a 2-sided 95% confidence interval of 0.20 was then calculated.
Similarly, as 20 of 30 Pfama1 sequences were identical, we tested
whether the frequency of the most common Pvama1 haplotype was
significantly different to 0.667.
Tests to determine any significant departure of variation from
neutrality using Tajima’s D [26] and Fu and Li’s D* and F* [27]
indices were performed in DNAsp v. 4.10 [28] on each gene
population as a whole and via a sliding window approach. Tajima’s
D tests the departure from neutral by comparing the estimations of
nucleotide diversity (h) derived from the average pairwise diversity
(p) and the total number of polymorphic sites. The Fu and Li tests
identify departures from neutral patterns of nucleotide substitutions
as deviations between the estimates of h derived from the number of
phylogenies compared to either the total number of mutations (D*)
or the averagepairwise diversity (F*). Analysis of recombinationand
linkage disequilibrium was performed to calculate the minimum
number of recombination events within each of the Pvama1 and
Pfama1 sequences [29] and to give an estimation of the
recombination parameter, C [30]. The indices of linkage disequi-
librium, D’ [31] and R
2 [32] were also determined and their
relationship with distance between sites was plotted.
Between population analyses
The Mc Donald-Kreitman test, using either P. cynomolgi
(accession number X86099) or P. knowlesi (accession numbers
AF298218, M58317, M61097) for outgroup comparisons with the
P. vivax populations, and P. reickenowi (accession number AJ252087)
for comparisons with P. falciparum, allows for determination of the
ratios of synonymous and nonsynonymous changes between and
within species. Between-population divergence of the Pvama1 data
presented here and previously published Pvama1 data for Domain I
(DI) from global sites [15,33,34,35] was determined using the h-
estimator of Wright’s fixation index (FST) to determine the relative
contribution of the differences observed between each population
to the overall diversity seen using Arlequin v.3.11 software [36]. As
only two previously published studies [15,35] allow comparisons
across the whole Pvama1 ectodomain, FST values in our dataset
were determined across the whole gene and for each of the
domains separately. Mean FST values for the Venezuelan Pfama1
sequences were compared with two published Pfama1 data sets
[18,19] that each includes all three domains, allowing determina-
tion of mean FST values for the full gene and each of the three
domains separately.
Results
Parasite samples
In the first survey, light microscopy determined 40 P. vivax,3 2P.
falciparum,1 6P. malariae and 2 mixed infections (one P. vivax with P.
Table 1. PCR primers and conditions.
Nest 1 Nest 2
Pvama1
1663 bp
Pvama1_F16 59 gcg gtt act tcc acc cc 39 Pvama1_F29 59 gca aac caa atc gct gcc 39
Pvama1_R613 59 gcg tgg tgt ggg agg ccc 39 Pvama1_R598 59 gcc tcg ggg tcg agc atc tcg tc 39
Nest 1 PCR: 94uC
3m i n 61 cycle,
(94uC
1m i n 246uC
1m i n 272uC
2.5 min)640 cycles,
72uC
10 min61
Nest 2 PCR: 94uC
3m i n 61 cycle, (94uC
1m i n 257uC
1m i n –
72uC
2.5 min)640 cycles, 72uC
10 min61
Fwd sequencing: Rev sequencing
Pvama1_F142 aga att cca gct gga aga tg Pvama1_R138 ttc cac ttc tgc atc ttc ccc
Pvama1_F301 cgt aaa aat tta gga aac gcc Pvama1_R293 aca ttt ttg ctc aaa tac acc
Pvama1_F441 ccc ctg cag cat ata taa aga c Pvama1_R442 ggg gaa atc ccg gtc tac ttc
Pfama1
1770 bp
Pfama1_F5* 59 tgc gta tta tta ttg agc 39 Pfama1_F10* 59 gag cgc ctt tga gtt tac 39
Pfama1_R613* 59 gtg ttg tat gtg atg ctc 39 Pfama1_R598* 59 gcc tca gga tct aac att tca tc 39
Nest 1 PCR: 94uC
3m i n 61 cycle,
(94uC
1m i n 246uC
1m i n 272uC
2.5 min)640 cycles,
72uC
10 min61
Nest 2 PCR: 94uC
3m i n 61 cycle,
(94uC
1m i n 260uC
1m i n 272uC
2.5 min)640 cycles,
72uC
10 min61
Fwd sequencing: Rev sequencing:
Pfama1_F143 gac ttc cat cag gga aat gtc c Pfama1_R188 gag gtt ctg ttg gag gaa aag c
Pfama1_F312 cgg att atg ggt cga tgg aaa ttg Pfama1_R350 tta ggt tga tcc gaa gca ctc aa
Pfama1_F485 gac agt tta aaa tgc cca tgt gc Pfama1_R492 cac atg ggc att tta aac tgt c
*(Polley & Conway, 2001).
doi:10.1371/journal.pone.0003366.t001
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In the second survey of 945 individuals, microscopy determined 92
P. vivax,1 2P. falciparum,2 0P. malariae and 3 mixed infections of P.
vivax with P. malariae. The overall malaria prevalence did not vary
between surveys being 12.7% in 1995/6 and 13.4% in 1997.
However, vivax malaria comprised a significantly greater propor-
tion of malaria infections in the second survey (O.R. 3.39, 95%
C.I. 1.83–6.29; P,0.0001), whereas falciparum was significantly
less common (O.R. 0.180, 95% C.I. 0.079–0.394; P,0.0001).
Full-length ama1 contigs with double sequence reads were
obtained for 73 P. vivax and 30 P. falciparum isolates (GenBank
accession nos. EU346015-EU346087 for Pvama1, and EU332414-
EU332443 for Pfama1). All sequences encoded cysteine residues in
previously described positions. Neither Pvama1 nor Pfama1
populations contained sequences identical to their respective
reference strains; Sal-1 (gene ID Pv092275 from http://www.
PlasmoDB.org) and 3D7 (accession number XM_001347979).
Within population analyses
Diversity among Pvama1 sequences was first analysed within
comparable groups: those from the 9 villages surveyed in 1995/6
(28 sequences), those collected from these 9 villages in the second
survey (12 sequences), and sequences collected from Koshiro-
wetheri village in the second survey (33 sequences). Diversity of the
Pfama1 gene was analysed in sequences from the 9 villages in the
first survey only (30 sequences).
Genetic diversity, as measured by h, is greater among the Pvama1
sequences than among the Pfama1 sequences (Table 2). This
remains true when isolates from Koshirowetheri are excluded from
the analysis, supporting the conclusion that there is a significant
increase in the circulating diversity of P. vivax at the Pvama1 locus
between the two years (Figure 1). Of the 73 Pvama1 sequences
obtained, there were 18 unique haplotypes, compared to 6 unique
haplotypes from 30 Pfama1 sequences (2-sided binomial probability,
P=0.308). However, among the 30 Pfama1 sequences 20 were of
the most common haplotype, whereas among the 73 Pvama1
sequences 15 were of the most common haplotype (P,0.001). The
overall diversity estimates for Pvama1 and Pfama1 (h=0.9091,
h=0.538 respectively) are consistent with our previous studies from
this regionusingrif,Pfglurp, Pfmsp1andPfmsp2genesforP.falciparum,
and using Pvmsp3a for P. vivax [22,23], and demonstrate greater
diversity in the P. vivax population.
The frequency of recombination within the Pvama1 population
is relatively high compared to the predicted frequency within the
Pfama1 population (10 minimum recombination events within 73
Pvama1 sequences vs. 3 in 30 Pfama1 sequences; Table 3), yet both
of these are low compared to estimates from other regions. Among
23 Pvama1 sequences from Sri Lanka, the estimated minimum
number of recombination events was 9 [15]. For Pfama1, analysis
of 50 isolates from Nigeria and 51 from Thailand provided
estimates of the minimum number of recombination events of 25
and 16 respectively [18,19]. Our linkage disequilibrium analysis
indicates declining inter-site linkage with increasing nucleotide
distance within the Pvama1 sequences, in contrast to the significant
linkage across the whole of the Pfama1 sequences (Figure 2.). The
very low value of the Pfama1 recombination parameter, C=0.001,
and the observed maintenance of significant linkage suggests very
little meiotic recombination occurs in this gene in our population,
supporting the view that clonal propagation of P. falciparum has
occurred over a significant period of time [23]. This is supported
by our estimation of en effective population size for P. vivax that is
4 orders of magnitude higher than that for P. falciparum (Table 2).
Evidence of selective signals in the two sequence sets was
provided by tests for neutrality of polymorphisms. Across the two
Table 2. Within-population analyses of Pvama1 and Pfama1 from the Venezuelan Amazon.
P. falciparum ama1 P. vivax ama1
1996 Villages 1–9 in 1996 Villages 1–9 in 1997 1997 Koshirowetheri
Number of sequences 30 28 12 33
Number of haplotypes
Whole gene 6 6 10 10
Domain I 5 5 6 9
Domain II 2 3 4 3
Domain III 3 2 3 2
Gene diversity, h
Whole gene 0.54 0.80 0.97 0.89
Domain I 0.45 0.78 0.68 0.86
Domain II 0.37 0.58 0.74 0.48
Domain III 0.42 0.50 0.59 0.41
Tajima’s D 1.73927
* 1.00507
** 20.48752 1.82661
Fu and Li’s D* 1.72279
*** 0.71243
** 20.53615 1.72312
***
Fu and Li’s F* 2.03574
*** 0.94666
** 20.59625 2.07362
***
Recombination parameter, C
(Between adjacent sites)
0.001 (0.000) 10.0 (0.0061) 14.7 (0.0090) 16.9 (0.0103)
Effective population size, Ne
{ 4.2610
2 4.2610
6 6.1610
6 7.0610
6
Minimum Recombination events, Rm 3 1 4 8
*=0.10.P.0.05;
**=P.0.10;
***=P,0.02.
{=Effective population size, Ne,=C/4r, where r is the recombination rate and r of P. falciparum is used for all, approximately 6610
27, as the recombination rate for P.
vivax has not yet been determined (Joy et al., 2006).
doi:10.1371/journal.pone.0003366.t002
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found for Pfama1, with Fu and Li’s D* and F* analyses providing
parameter values of 1.72279 and 2.03574 (P,0.02 in each case)
respectively. For pvama1, sequences from the 1997 survey gave
significant values for Tajima’s D and Fu and Li’s F* across domain
1 only (data not shown). Sliding window analyses were also
performed to identify any departures from neutral patterns of
nucleotide substitution across smaller regions within both genes.
Plots of each of these analyses, with the individual domains
highlighted, are shown in Figure 3. As with other studies
[15,33,34], a region of DI of Pvama1 within this Venezuelan
population shows a significantly positive departure from neutral
substitution patterns, indicating that balancing selection may be
maintaining alleles of this domain. However, unlike previous
studies [15], no evidence was found of balancing or directional
selection upon DII or DIII in Pvama1 sequences from this
Venezuelan population, and the values for these two domains
are effectively zero (minimally positive and minimally negative in
many cases). Like the Pvama1 data, Pfama1 showed a significant
positive departure from neutrality in DI. The trend across the
other two domains matches published Nigerian and Thai data of
Polley et al. [18,19], in that evidence of allele maintenance by
balancing selection was stronger in DIII than within DII, although
this was not significant in our study population.
Between population analyses
We also examined the two sequence sets for evidence of
selection using the McDonald-Kreitman test, which compares the
Table 3. McDonald-Kreitman analyses of Pvama1 and Pfama1.
Region
Polymorphic
changes within
species
Polymorphic
changes within
species
Fixed differences
between species
Fixed differences
between species
Neutrality
index
1
Fisher’s
exact test
2
Synonymous Nonsynonymous Synonymous Nonsynonymous
P. vivax vs Whole 6 21 119 69 6.04 0.000095**
P. cynomolgi DI 3 11 35 19 6.75 0.0057*
DII 2 2 21 11 1.91 0.61
DIII 0 2 12 10 - 0.48
P. vivax vs Whole 9 22 130 82 3.88 0.00086**
P. knowlesi DI 4 12 37 21 5.29 0.0095*
DII 2 2 20 21 1.67 1.00
DIII 1 2 15 3 10.00 0.13
P. falciparum vs Whole 0 29 19 53 - 0.0013*
P. reickenowi DI 0 14 4 10 - 0.098
DII 0 5 3 4 - 0.20
DIII 0 3 1 5 - 1.00
1=Neutrality index indicates the extent to which the levels of amino acid polymorphism depart from the expected in the neutral model.
2=Fisher’s exact test.
*0.001,P,0.01; ** P,0.001.
doi:10.1371/journal.pone.0003366.t003
Figure 1. Graphical representation of the distributions of the Pvama1 and Pfama1 allele frequencies from the Venezuelan Amazon.
A. Distribution of 18 Pvama1 haplotypes across surveys in 1996 and 1997. Sequences from the additional village sampled in 1997 (Koshiro) are
presented separately from those of the villages sampled in both surveys. B. Haplotype frequency distribution for Pfama1 and Pvama1 from the 1996
survey only.
doi:10.1371/journal.pone.0003366.g001
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within the species, to the relative frequency of fixed differences
between this and a related species. Data are summarised in
Table 3, and support results from the tests of neutrality, as alleles
within these Venezuelan Pvama1 and Pfama1 populations,
particularly within DI, have significantly more non-synonymous
substitutions than expected from comparison with related species.
Thus diversifying selection is maintaining ama1 allelic diversity in
both P. falciparum and P. vivax in our population.
There are 12, 4 and 3 Pvama1 haplotypes within this studied
Venezuelan population across DI, DII and DIII, respectively.
When this Venezuelan data is added to previously published data
[15,33,34,35], there are 90 described haplotypes across DI, 11 of
which are unique to Venezuela; 8 haplotypes across DII, 1 unique
to Venezuela; 4 haplotypes across DIII, none unique to
Venezuela. This observed greater overlap of haplotypes across
DII and DIII between samples from geographically diverse regions
may be due simply to the scarcity of polymorphic sites in these
smaller domains, exacerbated by the fact that only two other
studies are available for comparison across these domains [15,35].
Inter-population comparison of Pvama1 sequences from all
available studies shows that the majority of diversity is within
each population and not among populations, as indicated by low
FST values (Tables 4 and 5).
The number of Pfama1 haplotypes observed in the Venezuelan
dataset is 6, 2 and 3 across DI, DII and DIII, respectively. When
added to previously published data from Nigeria and Thailand
[18,19], there are 58 haplotypes across DI, 5 of which are unique
to Venezuela; 26 haplotypes across DII, none unique to
Venezuela; 17 haplotypes across DIII, none of them unique to
Venezuela. Pairwise inter-population comparisons show there is a
significant diversity between population pairs, particularly across
DI, with generally higher FST values than for Pvama1 (Table 5).
Discussion
We have analysed diversity in full length gene sequences
encoding the apical membrane antigen (AMA1), from 73 P. vivax
and 30 P. falciparum isolates collected in the same cross-sectional
surveys of an isolated human population. To our knowledge, this is
the first such detailed analysis of two homologous genes in
sympatric Plasmodium parasite populations. The majority of people
present at the time of the surveys agreed to provide blood samples
for analysis, irrespective of malaria status, and so these surveys
represent a good sample of both co-circulating P. vivax and P.
falciparum [22,23]. This is an important strength of our study,
compared to analyses of symptomatic cases that have presented
passively at health facilities with undefined catchment areas.
Previous studies had suggested that P. vivax and P. falciparum
circulating in the Padamo exhibited very different population
structures, but a direct test of this hypothesis required detailed
analysis of homologous genes in the two species populations, so
Figure 2. Linkage disequilibrium indices of Pvama1 and Pfama1. Linkage disequilibrium plots of D’ and R
2 for Pvama1 (Graphs A and B) and
Pfama1 (Graphs C and D). Sites with significant linkage (P,0.05) are shown as solid circles; non-significant sites are shown as for Pvama1 only. No
non-significant sites for Pfama1 were found.
doi:10.1371/journal.pone.0003366.g002
ama1 in Sympatric Malaria
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3366that the magnitude and effect of selection would be as similar as
possible in the two datasets. AMA1 is a well-characterised parasite
protein in both species, with homologues in all Plasmodium spp.
examined, and is currently being tested as a vaccine candidate for
P. falciparum. AMA1 contributes to the reorientation of merozoites,
and is located at the tight junction during ingress of the
erythrocyte. AMA1 also has a role in sporozoite invasion of
hepatocytes [37,38,39,40].
Genetic diversity was found to be significantly higher in the P.
vivax population, and indices of intra-population recombination
were significantly lower in the P. falciparum population. In contrast,
indices of selective diversification on the two gene populations
were similar, suggesting that differences in functional and
immunological constraints upon them could not explain differ-
ences in gene diversity, and the frequency of recombination. We
therefore conclude that whereas the P. vivax population is
comprised of a diverse gene pool that frequently undergoes
recombination, the P. falciparum population exhibits restricted
diversity and appears to propagate most commonly by clonal
expansion, with minimal opportunities for recombination. These
findings are wholly consistent with the observation of stable multi-
locus genotypes supported by high levels of inter-genic linkage
disequilibrium among the P. falciparum population in the Padamo.
As argued previously, this strongly suggests that this parasite
population has passed through an evolutionary bottleneck which
has both restricted genetic diversity and reduced opportunities for
recombination within the population [23]. In contrast, we found
no evidence that the P. vivax population has also passed through
such a bottleneck. Evidence of a similar difference in structure
between these two species has been observed in a study of 11
isolates of each from Papua New Guinea [41]. Interestingly, our
earlier analysis of var gene sequences in the Padamo P. falciparum
population indicated that these genes partially transcended the
clonal structure observed at other loci, supporting the view that
this gene family recombines, and evolves, at a higher frequency
than do other loci in P. falciparum [42].
The majority of diversity seen among the Venezuelan ama1
sequences is in DI of both P. vivax and P. falciparum and, in
accordance with other global studies, this domain accounts for the
majority of distinct haplotypes within a population. However, the
polymorphisms generating this diversity do not demonstrate
neutral patterns of substitution. The pattern of polymorphisms
seen in DI show a significant positive departure from neutral,
suggesting they are under biological functional constraints as well
Figure 3. Sliding window plots of Tajima’s D and Fu and Li’s F* for Pvama1 and Pfama1. A and B – Pvama1; C and D – Pfama1. Midpoints
where the sequence significantly departs from zero (P,0.05) are shown as solid points. Domains, DI, DII, DIII, are marked.
doi:10.1371/journal.pone.0003366.g003
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‘balancing selection’ in DI of ama1 across global isolates suggests
this region is a target of natural host immunity, and supports the
development of this domain as a potential vaccine target in both P.
vivax and P. falciparum.
The importance of DII is less clear. In this Venezuelan
population, there is no evidence to suggest balancing selection
has contributed to the pattern of polymorphic substitution neither
in DII nor in DIII of either species. Previous data confirms this
finding for Pfama1 [18,19], but this is contradictory to available
Pvama1 data [15]. However, the Pvama1 sequences from this
smaller Sri Lanka dataset (N=23) were derived from clinical
malaria presentations, and it is unknown how those alleles seen
compare to the full repertoire of alleles present within the
circulating P. vivax population from that region. Such differences in
sampling procedure may also explain the neutral pattern of
substitution across DIII observed among the Venezuelan Pvama1
sequences, in contrast to DIII from other regions.
Low sample numbers may have inhibited our analyses of the
Venezuelan Pfama1 sequences by reducing the power needed to
identify significant changes or signals of selection beyond those
identified in DI. Only 30 Pfama1 sequences were obtained, all from
the first survey in 1996. Yet, as only 33 individuals were slide
positive for P. falciparum in this year (one of which was a mixed
Table 4. Geographical differences in Pvama1 sequences across DI only.
Venezuela
a
Venezuela
b 0.140 Venezuela
b
Venezuela
c 0.059 0.824 Venezuela
1
Sri Lanka
2 0.125 Sri Lanka (23)
Thailand
3 0.135 0.122 Thailand (8)
ADS
4 0.170 0.152 0.139 ADS (21)
Africa
4 0.134 0.003 0.104 0.156 Africa (5)
China
4 0.092 0.075 0.020 0.096 0.047 China (7)
India
4 0.085 0.034 0.081 0.126 0.044 0.032 India (18)
Indonesia
4 0.072 0.043 0.059 0.116 0.050 0.000 20.011 Indonesia (5)
Morong
4 0.146 0.128 0.107 0.155 0.115 0.084 0.099 0.078 Morong (110)
Palawan
4 0.163 0.143 0.139 20.012 0.146 0.091 0.117 0.094 0.155 Palawan (17)
PNG
4 0.107 0.097 0.045 0.120 0.029 0.016 0.050 0.022 0.102 0.112 PNG (23)
Solomons
4 0.131 0.123 20.007 0.151 0.097 0.048 0.075 0.051 0.125 0.142 0.009 Solomons (7)
Thailand
4 0.074 20.008 20.007 0.112 20.020 0.000 20.014 20.034 0.078 0.102 0.007 20.024 Thailand (6)
India (33)
5 0.109 0.066 0.089 0.137 0.050 0.039 0.011 0.023 0.109 0.128 0.054 0.083 0.009
Pairwise FST values between Venezuelan sequences presented here and other sites only are highlighted.
a=1996 villages, N=28;
b=1997 villages, N=12;
c=Koshirowetheri 1997 only, N=33;
1=all Venezuela data irrespective of village, N=73;
2=[15];
3=[33];
4=[34];
5=[35]; Sample sizes available are shown in parenthesis
after each location; Significant difference (P,0.05) indicated by bold underline. Slightly negative numbers, indicated by italics, are biologically meaningless and are
equivalent to FST=0.000.
doi:10.1371/journal.pone.0003366.t004
Table 5. Geographical differences in Pvama1 and Pfama1 sequences across all domains.
P. vivax ama1 pairwise
FST estimates
Venezuela (73)
1 P. falciparum ama1 pairwise
FST estimates
Venezuela (30)
2
Sri Lanka (23)
2 Nigeria (50)
4
Whole 0.074 Whole 0.258
DI 0.120 DI 0.265
DII 0.185 DII 0.192
DIII 0.322 Sri Lanka DIII 0.240 Nigeria
India
3 Thailand (51)
5
Whole (33) 0.091 0.048 Whole 0.273 0.019
DI (33) 0.109 0.058 DI 0.286 0.039
DII (34) 0.034 0.223 DII 0.344 0.086
DIII (34) 0.349 20.035 DIII 0.276 0.056
Pairwise FST values between Venezuelan sequences and other sites are highlighted. Sample sizes are in parenthesis.
1=all Venezuela Pvama1data from both 1996 and
1997;
2=all Venezuela Pfama1 data from 1996 only;
2=[15];
3=[35] one sequence was ignored in the whole gene and DI analysis as it was not full length;
4=[19];
5=[18]. Significant difference (P,0.05) indicated by bold text. Slightly negative numbers, indicated by italics, are biologically meaningless and are equivalent to
FST=0.000.
doi:10.1371/journal.pone.0003366.t005
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potential lack of power within Pfama1 is shown in DIII. Although
the trend follows that previously described, there is no significant
evidence to conclude this domain is also under balancing selection.
ThereisamarkeddifferenceintheprevalenceofP.vivaxinfections
between the two surveys. The second survey in 1997 followed a
period of low rainfall which effectively interrupted mosquito-borne
transmission for that season [23]. P. falciparum prevalence (slide
positive) dropped from 4.7% to 1.3% but P. vivax increased from
5.5% in 1996 to 9.8% in 1997. P. malariae prevalence remained
similar (2.3% and 2.1% respectively) as did the overall burden of
malaria 212.7% in 1996 to 13.44% in 1997. In the Venezuelan
Amazon, both P. vivax and P. falciparum are transmitted by the
predominant vector species, Anopheles darlingi, and an interruption of
transmission would affect both parasite species equally.
We suggest the increase of prevalence of P. vivax regardless of
reduced transmission is a result of new merozoites being released
from dormant hypnozoites (relapse). In the presence of active P.
falciparum infection, such emergent P. vivax blood-stages may be
prevented from establishing an infection by cross-species regula-
tion and suppression [7,9]. The presence of circulating P. falciparum
may have effectively limited P. vivax infection in the previous (wet)
year, but during a season with greatly reduced transmission, these
new merozoites are able to expand significantly within their
individual hosts. It has usually been assumed that genotypes seen
as a result of relapses will always be representative of those
genotypes previously seen, i.e. those of a primary infection [43,44].
If true, then even though the actual numbers of P. vivax increased
from one survey to the next in this Venezuelan study, the genetic
profiles between the two samples would be expected to be similar.
We found a greater apparent diversity in Pvama1 sequences from
the 1997 survey, with whole gene diversity h=0.913 compared to
h=0.796 in 1996. This may be partially due to the lower number
of isolates obtained in the first survey, and given the large effective
population size we have estimated for P. vivax, we cannot be
certain our two cross-sectional samples were sufficiently represen-
tative to permit comparison of P. vivax diversity between surveys.
Pairwise FST values show small but significant differences between
Pvama1 sequence sets between these two years across the whole
gene (9.1%) and across the polymorphic region of DI only (6.3%).
We cannot determine whether any apparent increase in diversity
in the second survey is due to relapse from heterologous
hypnozoites, as we did not successfully amplify Pvama1 from any
sample pairs of individuals that were P. vivax positive in both 1996
and 1997 surveys (there were 3 such people). Further work on
pvama1 diversity in larger samples from this population would be
required to compare with recent findings from Thailand, India
and Myanmar which suggest that relapse of P. vivax in these
regions is usually from activation of heterologous hypnozoites [45].
Of the four Plasmodium species that infect humans, P. vivax and P.
falciparum are the two that are most often sympatric. Despite this,
control regimes have usually targeted only P. falciparum in isolation,
and in many cases the contribution of P. vivax to the local and global
malarial burden has been ignored [1]. Substantial differences in the
level of genetic diversity between these two species in the Padamo
are consistent with one of them, P. falciparum, having passed through
an evolutionary bottleneck either at the time of the introduction of
this species to Venezuela from Europe and Africa or due to more
recent constraints on recombination, whereas the P. vivax
population displays evidence of a distinct recent evolutionary
history in which diversity is maintained, and recombination is
common. Whereas the former species displays characteristics of an
epidemicpopulationstructure,P.vivaxexhibitsastructureconsistent
with that of an established endemic pathogen. Our data thus
demonstrate that these two human pathogens adopt different
strategies to survive in this setting of mesoendemic transmission in
the Venezuelan Amazon, and as a result differ in their susceptibility
to changing environmental conditions, and seasonal fluctuations in
vector abundance. Future control regimes and interventions
therefore need to include strategies that will target each of the
parasite populations present, and so aim to reduce the overall
malarial burden.
Acknowledgments
We thank Spencer Polley for helpful discussions and comments on the
manuscript. Study participants gave informed consent for genetic studies to
be carried out on the parasite isolates, at the time they were collected.
Author Contributions
Conceived and designed the experiments: RO CJS. Performed the
experiments: RO. Analyzed the data: RO. Contributed reagents/
materials/analysis tools: RO AT CJS. Wrote the paper: RO CJS.
References
1. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of
Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97–106.
2. Guerra CA, Snow RW, Hay SI (2006) Mapping the global extent of malaria in
2005. Trends Parasitol 22: 353–358.
3. Mueller I, Zimmerman PA, Reeder JC (2007) Plasmodium malariae and
Plasmodium ovale - the ‘bashful’ malaria parasites. Trends Parasitol 23:
278–283.
4. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, et al. (2003) Genetic
diversity and multiple infections of Plasmodium vivax malaria in Western
Thailand. Am J Trop Med Hyg 68: 613–619.
5. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, et al.
(2007) Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and
Association with Molecular Polymorphisms. PLoS ONE 2: e1089.
6. Maitland K, Williams TN, Bennett S, Newbold CI, Peto TE, et al. (1996) The
interaction between Plasmodium falciparum and P. vivax in children on Espiritu
Santo island, Vanuatu. Trans R Soc Trop Med Hyg 90: 614–620.
7. Maitland K, Williams TN, Newbold CI (1997) Plasmodium vivax and P.
falciparum: Biological interactions and the possibility of cross-species immunity.
Parasitol Today 13: 227–231.
8. Smith T, Genton B, Baea K, Gibson N, Narara A, et al. (2001) Prospective risk
of morbidity in relation to malaria infection in an area of high endemicity of
multiple species of Plasmodium. Am J Trop Med Hyg 64: 262–267.
9. Bruce MC, Day KP (2002) Cross-species regulation of malaria parasitaemia in
the human host. Curr Opin Microbiol 5: 431–437.
10. Mason DP, Krudsood S, Wilairatana P, Viriyavejakul P, Silachamroon U, et al.
(2001) Can treatment of P. vivax lead to a unexpected appearance of falciparum
malaria? Southeast Asian J Trop Med Public Health 32: 57–63.
11. Baird JK (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob
Agents Chemother 48: 4075–4083.
12. Rieckmann KH, Davis DR, Hutton DC (1989) Plasmodium vivax resistance to
chloroquine? Lancet 2: 1183–1184.
13. Maguire JD, Sumawinata IW, Masbar S, Laksana B, Prodjodipuro P, et al.
(2002) Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia.
Lancet 360: 58–60.
14. Tan-ariya P, Pasuralertsakul S (1994) First report of in vitro susceptibility of
Plasmodium malariae Thai isolates to chloroquine. Southeast Asian J Trop Med
Public Health 25: 784–787.
15. Gunasekera AM, Wickramarachchi T, Neafsey DE, Ganguli I, Perera L, et al.
(2007) Genetic diversity and selection at the Plasmodium vivax apical membrane
antigen-1(PvAMA-1) locus in a Sri Lankan population. MolBiolEvol24: 939–947.
16. Franks S, Baton L, Tetteh K, Tongren E, Dewin D, et al. (2003) Genetic
diversity and antigenic polymorphism in Plasmodium falciparum: extensive
serological cross-reactivity between allelic variants of merozoite surface protein
2. Infect Immun 71: 3485–3495.
17. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) A diversity-covering
approach to immunization with Plasmodium falciparum apical membrane
antigen 1 induces broader allelic recognition and growth inhibition responses in
rabbits. Infect Immun 76: 2660–2670.
ama1 in Sympatric Malaria
PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e336618. Polley SD, Chokejindachai W, Conway DJ (2003) Allele frequency-based
analyses robustly map sequence sites under balancing selection in a malaria
vaccine candidate antigen. Genetics 165: 555–561.
19. Polley SD, Conway DJ (2001) Strong diversifying selection on domains of the
Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158:
1505–1512.
20. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, et al. (2004)
Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion
of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 52:
159–168.
21. Grynberg P, Fernandes Fontes CJ, Braga EM (2007) Association between
particular polymorphic residues on apical membrane antigen 1 (AMA-1) and
platelet levels in patients with vivax malaria. Clin Microbiol Infect 13:
1089–1094.
22. Ord R, Polley S, Tami A, Sutherland CJ (2005) High sequence diversity and
evidence of balancing selection in the Pvmsp3alpha gene of Plasmodium vivax in
the Venezuelan Amazon. Mol Biochem Parasitol 144: 86–93.
23. Tami A, Grundmann H, Sutherland C, McBride JS, Cavanagh DR, et al. (2002)
Restricted genetic and antigenic diversity of Plasmodium falciparum under
mesoendemic transmission in the Venezuelan Amazon. Parasitology 124:
569–581.
24. Ord RL (2008) Genetic Diversity of Plasmodium vivax and Plasmodium
falciparum co-circulating among the same hosts in the Venezuelan Amazon.
London: London School of Hygiene and Tropical Medicine, University of
London. 249 p.
25. Sutherland CJ, Alloueche A, Curtis J, Drakeley CJ, Ord R, et al. (2002)
Gambian children successfully treated with chloroquine can harbor and transmit
Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med
Hyg 67: 578–585.
26. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by
DNA polymorphism. Genetics 123: 585–595.
27. Fu YX, Li WH (1993) Statistical tests of neutrality of mutations. Genetics 133:
693–709.
28. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R (2003) DnaSP, DNA
polymorphism analyses by the coalescent and other methods. Bioinformatics 19:
2496–2497.
29. Hudson RR, Kaplan NL (1985) Statistical properties of the number of
recombination events in the history of a sample of DNA sequences. Genetics
111: 147–164.
30. Hudson RR (1987) Estimating the recombination parameter of a finite
population model without selection. Genet Res 50: 245–250.
31. Lewontin RC (1964) The Interaction of Selection and Linkage. I. General
Considerations; Heterotic Models. Genetics 49: 49–67.
32. Hill WG, Roberts A (1968) Linkage disequilibrium in finite populations.
Theoretical and Applied Genetics 38: 226–231.
33. Cheng Q, Saul A (1994) Sequence analysis of the apical membrane antigen I
(AMA-1) of Plasmodium vivax. Mol Biochem Parasitol 65: 183–187.
34. Figtree M, Pasay CJ, Slade R, Cheng Q, Cloonan N, et al. (2000) Plasmodium
vivax synonymous substitution frequencies, evolution and population structure
deduced from diversity in AMA 1 and MSP 1 genes. Mol Biochem Parasitol 108:
53–66.
35. Rajesh V, Elamaran M, Vidya S, Gowrishankar M, Kochar D, et al. (2007)
Plasmodium vivax: Genetic diversity of the apical membrane antigen-1 (AMA-1)
in isolates from India. Exp Parasitol 116: 252–256.
36. Excoffier L, Laval G, Schneider S (2005) Arlequin ver. 3.0: An integrated
software package for population genetics data analysis. Evolutionary Bioinfor-
matics Online 1: 47–50.
37. Hehl AB, Lekutis C, Grigg ME, Bradley PJ, Dubremetz JF, et al. (2000)
Toxoplasma gondii homologue of plasmodium apical membrane antigen 1 is
involved in invasion of host cells. Infect Immun 68: 7078–7086.
38. Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH (2004)
Apical membrane antigen 1, a major malaria vaccine candidate, mediates the
close attachment of invasive merozoites to host red blood cells. Infect Immun 72:
154–158.
39. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) Apical membrane
antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74–84.
40. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, et al. (2004) A role for
apical membrane antigen 1 during invasion of hepatocytes by Plasmodium
falciparum sporozoites. J Biol Chem 279: 9490–9496.
41. Mueller I, Kaiok J, Reeder JC, Cortes A (2002) The population structure of
Plasmodium falciparum and Plasmodium vivax during an epidemic of malaria in
the Eastern Highlands of Papua New Guinea. Am J Trop Med Hyg 67:
459–464.
42. Tami A, Ord R, Targett GA, Sutherland CJ (2003) Sympatric Plasmodium
falciparum isolates from Venezuela have structured var gene repertoires. Malar J
2: 7.
43. Kirchgatter K, del Portillo HA (1998) Molecular analysis of Plasmodium vivax
relapses using the MSP1 molecule as a genetic marker. J Infect Dis 177:
511–515.
44. Craig AA, Kain KC (1996) Molecular analysis of strains of Plasmodium vivax
from paired primary and relapse infections. J Infect Dis 174: 373–379.
45. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al.
(2007) Relapses of Plasmodium vivax infection usually result from activation of
heterologous hypnozoites. J Infect Dis 195: 927–933.
46. Su X, Ferdig MT, Huang Y, Huynh CQ, Liu A, et al. (1999) A genetic map and
recombination parameters of the human malaria parasite Plasmodium
falciparum. Science 286: 1351–1353.
ama1 in Sympatric Malaria
PLoS ONE | www.plosone.org 10 October 2008 | Volume 3 | Issue 10 | e3366